Should I buy or sell Cytokinetics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks .

What is Cytokinetics' stock price target for 2024?

15 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $80.00. On average, they predict the company's stock price to reach $59.87 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts .

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 28.9% and is now trading at $32.56. View the best growth stocks for 2023 here .

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our CYTK earnings forecast .

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.63. The biopharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $24.71 million.

What ETFs hold Cytokinetics' stock?

ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH) , American Century Mid Cap Growth Impact (MID) , BNY Mellon Innovators ETF (BKIV) , Fidelity Disruptive Medicine ETF (FMED) , SPDR S&P Biotech ETF (XBI) , Invesco S&P SmallCap 600 Pure Growth ETF (RZG) , Invesco S&P SmallCap Momentum ETF (XSMO) and Principal Healthcare Innovators ETF (BTEC) .

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com . Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA) , Arena Pharmaceuticals (ARNA) , OncoSec Medical (ONCS) , Novavax (NVAX) , Amgen (AMGN) , Inovio Pharmaceuticals (INO) , Sorrento Therapeutics (SRNE) , Dynavax Technologies (DVAX) , TherapeuticsMD (TXMD) and Gilead Sciences (GILD) .

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (12.23%), Wellington Management Group LLP (8.15%), American Century Companies Inc. (2.27%), Invesco Ltd. (1.21%), Northern Trust Corp (1.09%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include B Lynne Parshall , Bvf Partners L P/Il, Ching Jaw , David Cragg , Edward M Md Kaye , Fady Ibraham Malik , John T Henderson, John T Henderson , L Patrick Gage , Mark A Schlossberg , Muna Bhanji , Robert I Blum, Robert I Blum , Robert Wong , Sandford D Smith, Sandford D Smith , Santo J Costa and Wendall Wierenga . View institutional ownership trends .

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK)

$32.56

-1.33 (-3.92%)

(As of 12/5/2023 ET)

Compare

Today's Range: $32.54
▼
$33.93
50-Day Range: $26.88
▼
$36.32
52-Week Range: $25.98
▼
$47.49

Volume: 1.22 million shs
Average Volume: 1.05 million shs
Market Capitalization: $3.19 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $59.87

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.93 Rating Score
Upside/Downside: 83.9% Upside
$59.87 Price Target
Short Interest: Bearish
14.64% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.64
Upright™ Environmental Score
News Sentiment: -0.32
Based on 3 Articles This Week
Insider Trading: Selling Shares
$2.33 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.74) to ($4.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

288th out of 948 stocks

Pharmaceutical Preparations Industry

114th out of 421 stocks

4.5

Analyst's Opinion

Consensus Rating
Cytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $59.87, Cytokinetics has a forecasted upside of 83.9% from its current price of $32.56.
Amount of Analyst Coverage
Cytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
14.64% of the float of Cytokinetics has been sold short.
Short Interest Ratio / Days to Cover
Cytokinetics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Cytokinetics has recently decreased by 3.11%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Cytokinetics does not currently pay a dividend.
Dividend Growth
Cytokinetics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cytokinetics has received a 73.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Cytokinetics is -0.64.

1.5

News and Social Media Coverage

News Sentiment
Cytokinetics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cytokinetics this week, compared to 4 articles on an average week.
Search Interest
Only 6 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
12 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,332,125.00 in company stock.
Percentage Held by Insiders
Only 3.80% of the stock of Cytokinetics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cytokinetics are expected to grow in the coming year, from ($4.74) to ($4.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytokinetics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytokinetics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTK Stock News Headlines

December 5, 2023 | markets.businessinsider.com

Positive Prescription Trends and Market Dynamics Reinforce Buy Rating for Cytokinetics

December 4, 2023 | markets.businessinsider.com

Buy Rating on Cytokinetics: Upcoming Catalysts and Long-Term Commercial Prospects

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

November 29, 2023 | finance.yahoo.com

Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND

November 29, 2023 | americanbankingnews.com

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Recommendation of "Moderate Buy" from Analysts

November 24, 2023 | money.usnews.com

Cytokinetics Inc

November 10, 2023 | markets.businessinsider.com

Anticipated SEQUOIA-HCM Study Results Influence Salim Syed’s Buy Rating for Cytokinetics

November 10, 2023 | msn.com

Goldman Sachs Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation

December 6, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

November 9, 2023 | markets.businessinsider.com

Paul Choi’s Buy Rating on Cytokinetics: Evaluating the Potential and Value of Aficamten and its Market Impact

November 9, 2023 | markets.businessinsider.com

Expert Ratings for Cytokinetics

November 8, 2023 | msn.com

B. Riley Securities Initiates Coverage of Cytokinetics (CYTK) with Buy Recommendation

November 6, 2023 | msn.com

Merck highlights list of healthcare stocks among Mizuho's top picks

November 3, 2023 | finance.yahoo.com

Cytokinetics Inc (CYTK) Reports Q3 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Cytokinetics Reports Third Quarter 2023 Financial Results

November 2, 2023 | finance.yahoo.com

Wall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to Trade

November 2, 2023 | markets.businessinsider.com

Buy Rating for Cytokinetics: Acquisition Potential and Strong Financial Position

November 1, 2023 | za.investing.com

Potential Cytokinetics acquirer might wait until pivotal data - Truist

October 31, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Axsome Therapeutics (AXSM)

October 31, 2023 | reuters.com

Cytokinetics exploring options after receiving takeover interest - Bloomberg News

October 31, 2023 | msn.com

Cytokinetics surges amid report of takeover interest

October 30, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: G1 Therapeutics (GTHX), Coherus Biosciences (CHRS) and Cytokinetics (CYTK)

October 27, 2023 | msn.com

Cytokinetics speculated to be a takeover target

October 23, 2023 | finance.yahoo.com

Cytokinetics to Announce Third Quarter Results on November 2, 2023

October 20, 2023 | msn.com

HC Wainwright & Co. Maintains Cytokinetics (CYTK) Buy Recommendation

October 20, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for Cytokinetics: Here's What You Need To Know

October 20, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (CYTK), Medtronic (MDT) and Option Care Health (OPCH)

See More Headlines

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYTK
CUSIP: N/A
CIK: 1061983
Web: www.cytokinetics.com
Phone: (650) 624-3000
Fax: 650-624-3010
Employees: 409
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $59.87
High Stock Price Target: $80.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +83.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.93
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-388,950,000.00
Net Margins: -6,736.12%
Pretax Margin: -6,739.96%
Return on Equity: N/A
Return on Assets: -61.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.22
Quick Ratio: 7.22

Sales & Book Value

Annual Sales: $7.82 million
Price / Sales: 408.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.14) per share
Price / Book: -28.56

Miscellaneous

Outstanding Shares: 98,054,000
Free Float: 94,328,000
Market Cap: $3.19 billion
Optionable: Optionable
Beta: 0.57

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Robert I. Blum (Age 59)
CEO, President & Director
Comp: $1.14M
Mr. Ching W. Jaw (Age 60)
Senior VP & CFO
Comp: $698.49k
Mr. Robert C. Wong (Age 55)
VP & Chief Accounting Officer
Comp: $463.75k
Dr. Fady Ibraham Malik FACC (Age 59)
M.D., Ph.D., Executive Vice President of Research & Development
Comp: $776.99k
Mr. Andrew M. Callos (Age 67)
Executive VP & Chief Commercial Officer
Comp: $745.4k
Dr. James A. Spudich Ph.D. (Age 81)
Co-Founder & Member of Scientific Advisory Board
Comp: $21.94k
Mr. Jeff Lotz
Vice President of Sales & Operations
Mr. Steven M. Cook (Age 64)
Senior Vice President of Supply Chain Operations & Technical Operations
Ms. Diane Weiser
Senior Vice President of Corporate Communications & Investor Relations
Ms. Kari K. Loeser J.D.
VP & Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings or view top-rated stocks.
What is Cytokinetics' stock price target for 2024?: 15 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $80.00. On average, they predict the company's stock price to reach $59.87 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts.
How have CYTK shares performed in 2023?: Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 28.9% and is now trading at $32.56.
View the best growth stocks for 2023 here.
When is Cytokinetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our CYTK earnings forecast.
How were Cytokinetics' earnings last quarter?: Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.63. The biopharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $24.71 million.
What ETFs hold Cytokinetics' stock?: ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO) and Principal Healthcare Innovators ETF (BTEC).

What is Robert I. Blum's approval rating as Cytokinetics' CEO?: 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.
What other stocks do shareholders of Cytokinetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).
Who are Cytokinetics' major shareholders?: Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (12.23%), Wellington Management Group LLP (8.15%), American Century Companies Inc. (2.27%), Invesco Ltd. (1.21%), Northern Trust Corp (1.09%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends.
How do I buy shares of Cytokinetics?: Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial